Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17-25).
Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernandez-Guerra M, Augustín S, Bañales J, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M; HEPAmet Registry. Ampuero J, et al. J Hepatol. 2020 Sep;73(3):740-741. doi: 10.1016/j.jhep.2020.06.018. Epub 2020 Jul 9. J Hepatol. 2020. PMID: 32654856 Free article. No abstract available.
Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.
Diago M, Castellano G, García-Samaniego J, Pérez C, Fernández I, Romero M, Iacono OL, García-Monzón C. Diago M, et al. Gut. 2006 Mar;55(3):374-9. doi: 10.1136/gut.2005.074062. Epub 2005 Sep 8. Gut. 2006. PMID: 16150856 Free PMC article. Clinical Trial.
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, Crespo J, Andrade R, Martínez-Bauer E, Pérez R, Testillano M, Planas R, Solá R, García-Bengoechea M, Garcia-Samaniego J, Muñoz-Sánchez M, Moreno-Otero R; TeraViC-4 Study Group. Sánchez-Tapias JM, et al. Gastroenterology. 2006 Aug;131(2):451-60. doi: 10.1053/j.gastro.2006.05.016. Gastroenterology. 2006. PMID: 16890599 Clinical Trial.
[Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis].
Buti M, Rodríguez Frías F, Calleja JL, Jardí R, Pons F, Crespo J, Casanovas T, Enríquez J, Carnicer F, Romero M, García Bengoechea M, Prieto M, García Samaniego J, Miras M, Pérez Roldán F, Rueda M, Esteban R. Buti M, et al. Med Clin (Barc). 2007 Oct 27;129(15):566-70. doi: 10.1157/13111710. Med Clin (Barc). 2007. PMID: 17988612 Clinical Trial. Spanish.
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R; Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Romero-Gómez M, et al. Hepatology. 2009 Dec;50(6):1702-8. doi: 10.1002/hep.23206. Hepatology. 2009. PMID: 19845037 Clinical Trial.
Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.
Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D, Rodriguez-Caravaca G, Bárcena R, Serra MA, Romero-Gómez M, Fernandez I, Garcia-Samaniego J, Fuente J, Solá R, Moreno-Otero R, Planas R; Group for the Assessment of Prevention of Cirrhosis Complications and Virological Response (APREVIR). Fernández-Rodríguez CM, et al. Am J Gastroenterol. 2010 Oct;105(10):2164-72; quiz 2173. doi: 10.1038/ajg.2010.294. Epub 2010 Aug 10. Am J Gastroenterol. 2010. PMID: 20700116
Pathogenesis of occult chronic hepatitis B virus infection.
de la Fuente RA, Gutiérrez ML, Garcia-Samaniego J, Fernández-Rodriguez C, Lledó JL, Castellano G. de la Fuente RA, et al. World J Gastroenterol. 2011 Mar 28;17(12):1543-8. doi: 10.3748/wjg.v17.i12.1543. World J Gastroenterol. 2011. PMID: 21472118 Free PMC article. Review.
Clinical significance of occult hepatitis B virus infection.
Romero M, Madejón A, Fernández-Rodríguez C, García-Samaniego J. Romero M, et al. World J Gastroenterol. 2011 Mar 28;17(12):1549-52. doi: 10.3748/wjg.v17.i12.1549. World J Gastroenterol. 2011. PMID: 21472119 Free PMC article. Review.
Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels.
Calleja JL, García-Samaniego J, Ruiz-Antorán B, Trapero M, Morillas R, de la Revilla J, Erdozaín JC, Espinosa MD, Suárez D, Solá R, Romero-Gómez M, Baños F, Alvarez MA; Management of HCV Infection and Normal Transaminases Spanish Study Group. Calleja JL, et al. J Gastroenterol Hepatol. 2012 Nov;27(11):1705-10. doi: 10.1111/j.1440-1746.2012.07214.x. J Gastroenterol Hepatol. 2012. PMID: 22742958
228 results